Skip to main content
Log in

Ruptured ectopic pregnancies following methotrexate treatment: clinical course and predictors for improving patient counseling

  • General Gynecology: Original Article
  • Published:
Reproductive Sciences Aims and scope Submit manuscript

Abstract

To determine the predictors for tubal rupture among women treated with methotrexate (MTX) for ectopic pregnancy. We performed a retrospective cohort analysis in a tertiary university-affiliated medical center. Medical records of 401 women who were diagnosed with ectopic pregnancy and were treated with MTX between January 2001 and June 2017 were reviewed. Forty-one women were diagnosed with ruptured ectopic pregnancy (study group) and 360 women with non-ruptured ectopic pregnancy (control group). Descriptive data and predictive variables for rupture ectopic pregnancy following MTX treatment were reviewed. Out of 122 women who failed MTX treatment, forty-one women had tubal rupture (33.6%). The median time interval from MTX treatment to tubal rupture was 6 days (1–25). β-hCG percentage change in the 48 h preceding MTX treatment and β-hCG level at day 0 were independent predictors for tubal rupture (odds ratio [OR] = 1.08, 95% confidence interval [CI] = 1.04–1.12, p < 0.001 for every percent change in β-hCG; OR = 1.001, 95% CI = 1.0003–1.002 for every unit change in β-hCG, respectively). In a decision tree analysis model, in women with β-hCG percentage increment >69% in the 48 h preceding methotrexate the probability for tubal rupture was 85%. Risk assessment for tubal rupture should be made before methotrexate treatment according to β-hCG dynamics and level. The absolute risk for tubal rupture in women with β-hCG increment<20% is low.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

Not applicable.

References

  1. Whitehead SJ, Berg CJ, Chang J. Pregnancy-related mortality due to cardiomyopathy: United States, 1991-1997. Obstet Gynecol. 2003;102(6):1326–31.

    PubMed  Google Scholar 

  2. Hajenius PJ, et al. Randomised trial of systemic methotrexate versus laparoscopic salpingostomy in tubal pregnancy. Lancet. 1997;350(9080):774–9.

    Article  CAS  Google Scholar 

  3. Hajenius PJ, et al. Interventions for tubal ectopic pregnancy. Cochrane Database Syst Rev. 2007;1:CD000324.

    Google Scholar 

  4. Woolas RP, et al. Influence of chemotherapy for gestational trophoblastic disease on subsequent pregnancy outcome. Br J Obstet Gynaecol. 1998;105(9):1032–5.

    Article  CAS  Google Scholar 

  5. Dudley PS, et al. Characterizing ectopic pregnancies that rupture despite treatment with methotrexate. Fertil Steril. 2004;82(5):1374–8.

    Article  Google Scholar 

  6. Lipscomb GH, et al. Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies. N Engl J Med. 1999;341(26):1974–8.

    Article  CAS  Google Scholar 

  7. Cohen A, et al. Methotrexate success rates in progressing ectopic pregnancies: a reappraisal. Am J Obstet Gynecol. 2014;211(2):128 e1-5.

    Article  Google Scholar 

  8. Practice Committee of American Society for reproductive. Medical treatment of ectopic pregnancy: a committee opinion. Fertil Steril. 2013;100(3):638–44.

    Article  Google Scholar 

  9. Barnhart, K., M. Esposito, and C. Coutifaris, An update on the medical treatment of ectopic pregnancy. Obstet Gynecol Clin N Am, 2000. 27(3): p. 653–667, viii.

  10. Barnhart KT, et al. The medical management of ectopic pregnancy: a meta-analysis comparing "single dose" and "multidose" regimens. Obstet Gynecol. 2003;101(4):778–84.

    PubMed  Google Scholar 

  11. Bonin L, et al. Predictive factors for the methotrexate treatment outcome in ectopic pregnancy: a comparative study of 400 cases. Eur J Obstet Gynecol Reprod Biol. 2017;208:23–30.

    Article  CAS  Google Scholar 

  12. Lee JH, et al. A risk prediction model for medical treatment failure in tubal pregnancy. Eur J Obstet Gynecol Reprod Biol. 2018;225:148–54.

    Article  Google Scholar 

  13. Hutchinson AP, et al. Risk factors and human chorionic gonadotropin trends in patients with ruptured tubal ectopic pregnancies despite methotrexate treatment. Gynecol Endocrinol. 2019;35(1):49–52.

    Article  CAS  Google Scholar 

  14. Lipscomb GH, et al. Management of separation pain after single-dose methotrexate therapy for ectopic pregnancy. Obstet Gynecol. 1999;93(4):590–3.

    CAS  PubMed  Google Scholar 

  15. Heard K, Kendall J, Abbott J. Rupture of ectopic pregnancy after medical therapy with methotrexate: a case series. J Emerg Med. 1998;16(6):857–60.

    Article  CAS  Google Scholar 

  16. Qayyum H, et al. Ruptured ectopic pregnancy with a negative urinary pregnancy test after methotrexate treatment - challenges of diagnosis in the emergency department. J Obstet Gynaecol. 2017;37(7):958–9.

    Article  Google Scholar 

  17. Cohen A, et al. The role of HCG increment in the 48h prior to methotrexate treatment as a predictor for treatment success. Eur J Obstet Gynecol Reprod Biol. 2017;211:103–7.

    Article  CAS  Google Scholar 

  18. Cabar FR, et al. Predictive factors of trophoblastic invasion into the ampullary region of the tubal wall in ectopic pregnancy. Hum Reprod. 2006;21(9):2426–31.

    Article  CAS  Google Scholar 

  19. Kiss H, et al. Proliferative cell activity in correlation to human chorionic gonadotrophin release of trophoblast tissue of tubal pregnancy. Hum Reprod. 1997;12(2):383–6.

    Article  CAS  Google Scholar 

Download references

Code availability

Not applicable.

Funding

No funding was received to assist with the preparation of this manuscript.

Author information

Authors and Affiliations

Authors

Contributions

Aviad Cohen - Protocol/project development, Data collection or management, Manuscript writing/editing, data analysis

Shikma Bar-on - Data management, Manuscript writing/editing

Yoni Cohen - Manuscript writing/editing, data and statistical analysis

Ori Sandel - Protocol/project development, Data collection

Yuval Fouks - Manuscript writing/editing data analysis

Tamar Tzur - Protocol/project development, Manuscript writing/editing

Nadav Michaan - data and statistical analysis

Ishai Levin - Protocol/project development, Manuscript writing/editing

Corresponding author

Correspondence to Aviad Cohen.

Ethics declarations

Ethics approval and consent to participate

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Tel-Aviv medical center IRB approval number: 0208–18-TLV.

Consent for publication

Not applicable.

Competing interests

The authors have no relevant financial or non-financial interests to disclose.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cohen, A., Bar-on, S., Cohen, Y. et al. Ruptured ectopic pregnancies following methotrexate treatment: clinical course and predictors for improving patient counseling. Reprod. Sci. 29, 1209–1214 (2022). https://doi.org/10.1007/s43032-022-00881-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s43032-022-00881-7

Keywords

Navigation